Thursday, 26 Apr 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
28 Feb 2017 Social Just like Oral Strategy Study (MTX+Tofa > Tofa), DREAM registry shows TNFi + MTX > TNFi.
27 Feb 2017 News High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab
23 Feb 2017 News Sirukumab Effective in Rheumatoid Arthritis
20 Feb 2017 News Abatacept Efficacy Giant Cell Arteritis
20 Feb 2017 Social Dr Mahadevan #RWCS17 ustekinumab has been approved for Crohns disease
17 Feb 2017 Social RT @DrRachelTate: No changes in safety, efficacy, or ab production in IFX vs inflectra. Eric Ruderman, MD & Arthur Kavanaugh, MD #rwcs2017…
17 Feb 2017 News Biosimilar Reports – February 2017
17 Feb 2017 Social Dr Kevin Winthrop at #RWCS2017 reviews DMARD/Biologic effects on vaccine responses. Most effected by RTX, least by…
17 Feb 2017 Social ORAL strategy trial shows Xeljanz +MTX = Humira +MTX; but was inferior as monoRx Xeljanz in 1152 RA pts over 12 mos
17 Feb 2017 Social RT @DrRachelTate: JAK profiles in vitro as described by Mark Genovese, MD @RheumNow @RWCSmtg
16 Feb 2017 News BEAM Study: Baricitinib Beats Placebo and Adalimumab in Rheumatoid Arthritis
16 Feb 2017 Social 100% of RA pts having all 3 factors(seropositivity; high IgG levels;detectable serum IL-33) will respond to Rituxan
15 Feb 2017 Social RT @DrRachelTate: JAK profiles in vitro as described by Mark Genovese, MD @RheumNow @RWCSmtg
15 Feb 2017 Social Correction: Abbvies JAK inhibitor ABT-494) has a name, Uptacitinib, is currently in phIII trials. #RWCS 2017 info from Dr. M Genovese
15 Feb 2017 News Baricitinib Approved in the EU for Use in Rheumatoid Arthritis
15 Feb 2017 Social Baricitinib (AKA Olumiant ) approved by EMA for use in EU for moderate-to-severe RA as monotherapy or combo w/ MTX
13 Feb 2017 Social In animal models, abatacept and tofacitinib shown effective in treating suppressing Chikungunya arthritis.
10 Feb 2017 News An Integrated Analysis of Tofacitinib Safety
08 Feb 2017 Social Clinical review of anti-GMCSF mAb-mavrilimumab. Preclinical, Phase I/II efficacy & safety in #RA; 60-70% ACR20 resp
04 Feb 2017 Social Sarilumab (anti-IL-6) "Kevzara" approved by Health Canada for the Rx of RA. Dose 200 mg sc EOW. Let IL6 Wars begin!